Illumina, Inc. (ILMN)

Sector: Technology
Industry: Laboratory Analytical Instruments
Country: United States
Exchange: NASDAQ
Market cap: $37.02B

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Latest financial period: June 28, 2026
Filed with the SEC: July 31, 2026
Estimated earnings date: October 29, 2026

Menu

Home

Compare

Next Earnings Reports

How this site works

Terms of use

About